<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34646278</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?</ArticleTitle><Pagination><StartPage>755333</StartPage><MedlinePgn>755333</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">755333</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2021.755333</ELocationID><Abstract><AbstractText>Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex interactions between the host's genetic background and several environmental factors that result in dysimmunity against the central nervous system. An old-aged association exists between MS and viral infections, capable of triggering and sustaining neuroinflammation through direct and indirect mechanisms. The novel Coronavirus, SARS-CoV-2, has a remarkable, and still not fully understood, impact on the immune system: the occurrence and severity of both acute COVID-19 and post-infectious chronic illness (long COVID-19) largely depends on the host's response to the infection, that echoes several aspects of MS pathobiology. Furthermore, other MS-associated viruses, such as the Epstein-Barr Virus (EBV) and Human Endogenous Retroviruses (HERVs), may enhance a mechanistic interplay with the novel Coronavirus, with the potential to interfere in MS natural history. Studies on COVID-19 in people with MS have helped clinicians in adjusting therapeutic strategies during the pandemic; similar efforts are being made for SARS-CoV-2 vaccination campaigns. In this Review, we look over 18 months of SARS-CoV-2 pandemic from the perspective of MS: we dissect neuroinflammatory and demyelinating mechanisms associated with COVID-19, summarize pathophysiological crossroads between MS and SARS-CoV-2 infection, and discuss present evidence on COVID-19 and its vaccination in people with MS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Bellucci, Rinaldi, Buscarinu, Reni&#xe8;, Bigi, Pellicciari, Morena, Romano, Marrone, Mechelli, Salvetti and Ristori.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellucci</LastName><ForeName>Gianmarco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buscarinu</LastName><ForeName>Maria Chiara</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroimmunology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reni&#xe8;</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigi</LastName><ForeName>Rachele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellicciari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morena</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Carmela</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marrone</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mechelli</LastName><ForeName>Rosella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>San Raffaele Roma Open University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvetti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Neurologico Mediterraneo Neuromed, Pozzilli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ristori</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroimmunology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EBV&#x2014;Epstein-Barr Virus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">virus</Keyword><Keyword MajorTopicYN="N">virus-host interactions</Keyword></KeywordList><CoiStatement>MS received research support and consulting fees from Biogen, Merck, Novartis, Roche, Sanofi, Teva. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34646278</ArticleId><ArticleId IdType="pmc">PMC8503550</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.755333</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron (2018) 97:742&#x2013;68. doi:&#xa0;10.1016/j.neuron.2018.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.01.021</ArticleId><ArticleId IdType="pubmed">29470968</ArticleId></ArticleIdList></Reference><Reference><Citation>Dendrou CA, Fugger L, Friese MA. Immunopathology of Multiple Sclerosis. Nat Rev Immunol (2015) 15:545&#x2013;58. doi: 10.1038/nri3871</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3871</ArticleId><ArticleId IdType="pubmed">26250739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordi I, Ricigliano VAG, Umeton R, Ristori G, Grassi F, Crisanti A, et al. . Noise in Multiple Sclerosis: Unwanted and Necessary. Ann Clin Trans Neurol (2014) 1:502&#x2013;11. doi:&#xa0;10.1002/acn3.72</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.72</ArticleId><ArticleId IdType="pmc">PMC4184780</ArticleId><ArticleId IdType="pubmed">25356421</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie RA. Mounting Evidence for a Multiple Sclerosis Prodrome. Nat Rev Neurol (2019) 15:689&#x2013;90. doi:&#xa0;10.1038/s41582-019-0283-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0283-0</ArticleId><ArticleId IdType="pubmed">31654040</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G. The Neurodegenerative Prodrome in Multiple Sclerosis. Lancet Neurol (2017) 16:413&#x2013;4. doi:&#xa0;10.1016/S1474-4422(17)30127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30127-8</ArticleId><ArticleId IdType="pubmed">28504102</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnands JMA, Zhu F, Kingwell E, Zhao Y, Evans C, Fisk JD, et al. . Prodrome in Relapsing-Remitting and Primary Progressive Multiple Sclerosis. Eur J Neurol (2019) 26:1032&#x2013;6. doi:&#xa0;10.1111/ene.13925</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13925</ArticleId><ArticleId IdType="pubmed">30714270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, et al. . Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol (2020) 77:58&#x2013;64. doi:&#xa0;10.1001/jamaneurol.2019.3238</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3238</ArticleId><ArticleId IdType="pmc">PMC6745051</ArticleId><ArticleId IdType="pubmed">31515562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakalacheva K, M&#xfc;nz C, L&#xfc;nemann JD. Viral Triggers of Multiple Sclerosis. Biochim Biophys Acta - Mol Basis Dis (2011) 1812:132&#x2013;40. doi:&#xa0;10.1016/j.bbadis.2010.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2010.06.012</ArticleId><ArticleId IdType="pmc">PMC7126972</ArticleId><ArticleId IdType="pubmed">20600868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricigliano VAG, Handel AE, Sandve GK, Annibali V, Ristori G, Mechelli R, et al. . EBNA2 Binds to Genomic Intervals Associated With Multiple Sclerosis and Overlaps With Vitamin D Receptor Occupancy. PloS One (2015) 10:1&#x2013;11. doi:&#xa0;10.1371/journal.pone.0119605</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0119605</ArticleId><ArticleId IdType="pmc">PMC4390304</ArticleId><ArticleId IdType="pubmed">25853421</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli R, Romano C, Reni&#xe8; R, Manfr&#xe8; G, Buscarinu MC, Marrone A, et al. . Viruses and Neuroinflammation in Multiple Sclerosis. Neuroimmunol Neuroinflamm (2021) 8:1&#x2013;15. doi:&#xa0;10.20517/2347-8659.2021.01</Citation><ArticleIdList><ArticleId IdType="doi">10.20517/2347-8659.2021.01</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol (2019) 19:141&#x2013;54. doi:&#xa0;10.1038/s41579-020-00459-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbarao K, Mahanty S. Respiratory Virus Infections: Understanding COVID-19. Immunity (2020) 52:905&#x2013;9. doi:&#xa0;10.1016/j.immuni.2020.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.004</ArticleId><ArticleId IdType="pmc">PMC7237932</ArticleId><ArticleId IdType="pubmed">32497522</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. . Complex Immune Dysregulation in COVID-19 Patients With Severe Respiratory Failure. Cell Host Microbe (2020), 1&#x2013;9. doi:&#xa0;10.1016/j.chom.2020.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. . The Immunology of Multisystem Inflammatory Syndrome in Children With COVID-19. Cell (2020) 183(4):968&#x2013;81.e7. doi:&#xa0;10.1016/j.cell.2020.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7474869</ArticleId><ArticleId IdType="pubmed">32966765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, et al. . Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell (2020) 1&#x2013;14. doi:&#xa0;10.1016/j.cell.2020.09.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.034</ArticleId><ArticleId IdType="pmc">PMC7489877</ArticleId><ArticleId IdType="pubmed">32991843</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YC, Bai WZ, Hashikawa T. The Neuroinvasive Potential of SARS-CoV2 may be at Least Partially Responsible for the Respiratory Failure of COVID-19 Patients. J Med Virol (2020), 552&#x2013;5. doi:&#xa0;10.1002/jmv.25728</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25728</ArticleId><ArticleId IdType="pmc">PMC7228394</ArticleId><ArticleId IdType="pubmed">32104915</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by Human Respiratory Coronaviruses. J Virol (2000) 74(19):8913&#x2013;21. doi:&#xa0;10.1128/jvi.74.19.8913-8921.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.19.8913-8921.2000</ArticleId><ArticleId IdType="pmc">PMC102086</ArticleId><ArticleId IdType="pubmed">10982334</ArticleId></ArticleIdList></Reference><Reference><Citation>Burks JS, Devald BL, Jankovsky LD, Gerdes JC. Two Coronaviruses Isolated From Central Nervous System Tissue of Two Multiple Sclerosis Patients. Science (1980) 209(4459):933&#x2013;4. doi:&#xa0;10.1126/science.7403860</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7403860</ArticleId><ArticleId IdType="pubmed">7403860</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart JN, Mounir S, Talbot PJ. Human Coronavirus Gene Expression in the Brains of Multiple Sclerosis Patients. Virology (1992) 191(1):502&#x2013;5. doi:&#xa0;10.1016/0042-6822(92)90220-J</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(92)90220-J</ArticleId><ArticleId IdType="pmc">PMC7131143</ArticleId><ArticleId IdType="pubmed">1413524</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M, Bansal V, Feschotte C. A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors. Cell Rep (2020) 32(12):108175. doi:&#xa0;10.1016/j.celrep.2020.108175</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108175</ArticleId><ArticleId IdType="pmc">PMC7470764</ArticleId><ArticleId IdType="pubmed">32946807</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, et al. . Frequent Neurologic Manifestations and Encephalopathy-Associated Morbidity in Covid-19 Patients. Ann Clin Trans Neurol (2020) 7(11):2221&#x2013;30. doi: 10.1002/acn3.51210</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51210</ArticleId><ArticleId IdType="pmc">PMC7664279</ArticleId><ArticleId IdType="pubmed">33016619</ArticleId></ArticleIdList></Reference><Reference><Citation>Fifi JT, Mocco J. COVID-19 Related Stroke in Young Individuals. Lancet Neurol (2020) 19:713&#x2013;5. doi:&#xa0;10.1016/S1474-4422(20)30272-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30272-6</ArticleId><ArticleId IdType="pmc">PMC7434432</ArticleId><ArticleId IdType="pubmed">32822622</ArticleId></ArticleIdList></Reference><Reference><Citation>Fridman S, Bullrich MB, Jimenez-Ruiz A, Costantini P, Shah P, Just C, et al. . Stroke Risk, Phenotypes, and Death in COVID-19: Systematic Review and Newly Reported Cases. Neurology (2020) 95(24):e3373&#x2013;85. doi:&#xa0;10.1212/wnl.0000000000010851</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000010851</ArticleId><ArticleId IdType="pubmed">32934172</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the Nervous System. Cell (2020) 183:16&#x2013;27.e1. doi:&#xa0;10.1016/j.cell.2020.08.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.028</ArticleId><ArticleId IdType="pmc">PMC7437501</ArticleId><ArticleId IdType="pubmed">32882182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodro M, Compta Y, Llans&#xf3; L, Esteller D, Doncel-Moriano A, Mesa A, et al. . Increased CSF Levels of IL-1&#x3b2;, IL-6, and ACE in SARS-CoV-2-Associated Encephalitis. Neurol Neuroimmunol Neuroinflamm (2020) 7(5):e821. doi:&#xa0;10.1212/NXI.0000000000000821</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000821</ArticleId><ArticleId IdType="pmc">PMC7357418</ArticleId><ArticleId IdType="pubmed">32611761</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: A Spectrum of Vascular and Acute Disseminated Encephalomyelitis (ADEM)-Like Pathology. Acta Neuropathol (2020) 140:1&#x2013;6. doi:&#xa0;10.1007/s00401-020-02166-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02166-2</ArticleId><ArticleId IdType="pmc">PMC7245994</ArticleId><ArticleId IdType="pubmed">32449057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. . Dysregulation of Brain and Choroid Plexus Cell Types in Severe COVID-19. Nature (2021), 1&#x2013;10. doi:&#xa0;10.1038/s41586-021-03710-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco S, Nicholas R, Reynolds R, Magliozzi R. Intrathecal Inflammation in Progressive Multiple Sclerosis. Int J Mol Sci (2020) 21:1&#x2013;11. doi:&#xa0;10.3390/ijms21218217</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218217</ArticleId><ArticleId IdType="pmc">PMC7663229</ArticleId><ArticleId IdType="pubmed">33153042</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Lorenzo S, Konings J, van der Pol S, Kamermans A, Amor S, van Horssen J, et al. . Inflammation of the Choroid Plexus in Progressive Multiple Sclerosis: Accumulation of Granulocytes and T Cells. Acta Neuropathol Commun (2020) 8:9. doi:&#xa0;10.1186/s40478-020-0885-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-0885-1</ArticleId><ArticleId IdType="pmc">PMC6998074</ArticleId><ArticleId IdType="pubmed">32014066</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas J, Rudolph H, Costa L, Faller S, Libicher S, W&#xfc;rthwein C, et al. . The Choroid Plexus Is Permissive for a Preactivated Antigen-Experienced Memory B-Cell Subset in Multiple Sclerosis. Front Immunol (2021) 11:618544. doi:&#xa0;10.3389/fimmu.2020.618544</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.618544</ArticleId><ArticleId IdType="pmc">PMC7870993</ArticleId><ArticleId IdType="pubmed">33574821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelic M, Pontarelli F, Woodworth L, Zhu C, Mahan A, Ren Y, et al. . RIPK1 Activation Mediates Neuroinflammation and Disease Progression in Multiple Sclerosis. Cell Rep (2021) 35(6):109112. doi:&#xa0;10.1016/j.celrep.2021.109112</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109112</ArticleId><ArticleId IdType="pmc">PMC8917516</ArticleId><ArticleId IdType="pubmed">33979622</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwabenland M, Sali&#xe9; H, Tanevski J, Killmer S, Lago MS, Schlaak AE, et al. . Deep Spatial Profiling of Human COVID-19 Brains Reveals Neuroinflammation With Distinct Microanatomical Microglia-T-Cell Interactions. Immunity (2021) 54(7):1594&#x2013;610. doi:&#xa0;10.1016/j.immuni.2021.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8188302</ArticleId><ArticleId IdType="pubmed">34174183</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Bartley CM, Chow RD, Pleasure SJ, Wilson MR, Farhadian Correspondence SF. Divergent and Self-Reactive Immune Responses in the CNS of COVID-19 Patients With Neurological Symptoms. Cell Rep Med (2021) 2(5):100288. doi:&#xa0;10.1016/j.xcrm.2021.100288</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100288</ArticleId><ArticleId IdType="pmc">PMC8091032</ArticleId><ArticleId IdType="pubmed">33969321</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E, Rocco A, et al. . High Frequency of Cerebrospinal Fluid Autoantibodies in COVID-19 Patients With Neurological Symptoms. Brain Behav Immun (2021) 93:415&#x2013;9. doi:&#xa0;10.1016/J.BBI.2020.12.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BBI.2020.12.022</ArticleId><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF, Lung K, Tso EY, Liu R, Chung TW, Chu M, et al. . Articles Triple Combination of Interferon Beta-1b, Lopinavir &#x2013; Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19 : An Open-Label, Randomised, Phase 2 Trial. Lancet (2020) 6736:1&#x2013;10. doi:&#xa0;10.1016/S0140-6736(20)31042-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31042-4</ArticleId><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosorich I, Dalla-Costa G, Sorini C, Ferrarese R, Messina MJ, Dolpady J, et al. . High Frequency of Intestinal TH17 Cells Correlates With Microbiota Alterations and Disease Activity in Multiple Sclerosis. Sci Adv (2017) 3(7):e1700492. doi:&#xa0;10.1126/sciadv.1700492</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.1700492</ArticleId><ArticleId IdType="pmc">PMC5507635</ArticleId><ArticleId IdType="pubmed">28706993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadowaki A, Quintana FJ. The Gut&#x2013;CNS Axis in Multiple Sclerosis. Trends Neurosci (2020) 43(8):622&#x2013;34. doi:&#xa0;10.1016/j.tins.2020.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.06.002</ArticleId><ArticleId IdType="pmc">PMC8284847</ArticleId><ArticleId IdType="pubmed">32650957</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser T, Akg&#xfc;n K, Proschmann U, Sellner J, Ziemssen T. The Role of TH17 Cells in Multiple Sclerosis: Therapeutic Implications. Autoimmun Rev (2020) 19(10):102647. doi:&#xa0;10.1016/j.autrev.2020.102647</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102647</ArticleId><ArticleId IdType="pubmed">32801039</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. . The Emerging Spectrum of COVID-19 Neurology: Clinical, Radiological and Laboratory Findings. Brain (2020) 143:3104&#x2013;20. doi:&#xa0;10.1093/brain/awaa240</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, et al. . SARS-CoV-2 can Induce Brain and Spine Demyelinating Lesions. Acta Neurochirurg (2020) 162:1491&#x2013;4. doi:&#xa0;10.1007/s00701-020-04374-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00701-020-04374-x</ArticleId><ArticleId IdType="pmc">PMC7197630</ArticleId><ArticleId IdType="pubmed">32367205</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon L, Varley J, Gontsarova A, Mallon D, Tona F, Muir D, et al. . COVID-19-Related Acute Necrotizing Encephalopathy With Brain Stem Involvement in a Patient With Aplastic Anemia. Neurol Neuroimmunol Neuroinflamm (2020) 7:789. doi:&#xa0;10.1212/NXI.0000000000000789</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000789</ArticleId><ArticleId IdType="pmc">PMC7286661</ArticleId><ArticleId IdType="pubmed">32457227</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19&#x2013;Associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features. Radiology (2020) 296:E119&#x2013;20. doi:&#xa0;10.1148/RADIOL.2020201187</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/RADIOL.2020201187</ArticleId><ArticleId IdType="pmc">PMC7233386</ArticleId><ArticleId IdType="pubmed">32228363</ArticleId></ArticleIdList></Reference><Reference><Citation>Handa R, Nanda S, Prasad A, Anand R, Zutshi D, Dass SK, et al. . Covid-19-Associated Acute Haemorrhagic Leukoencephalomyelitis. Neurol Sci (2020) 41:3023&#x2013;6. doi:&#xa0;10.1007/s10072-020-04703-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04703-z</ArticleId><ArticleId IdType="pmc">PMC7462963</ArticleId><ArticleId IdType="pubmed">32876775</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadan B, Shankar A, Rajakumar A, Subramanian S, Sathya AC, Hakeem AR, et al. . Acute Hemorrhagic Leukoencephalitis in a COVID-19 Patient&#x2014;a Case Report With Literature Review. Neuroradiology (2021) 63:1. doi:&#xa0;10.1007/S00234-021-02667-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00234-021-02667-1</ArticleId><ArticleId IdType="pmc">PMC7878029</ArticleId><ArticleId IdType="pubmed">33575849</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Olivera A, Mueller N, Howard J, Lewis A. Delayed SARS-COV-2 Leukoencephalopathy Without Severe Hypoxia. J Neurol Sci (2020) 418:117146. doi:&#xa0;10.1016/J.JNS.2020.117146</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JNS.2020.117146</ArticleId><ArticleId IdType="pmc">PMC7500274</ArticleId><ArticleId IdType="pubmed">32977227</ArticleId></ArticleIdList></Reference><Reference><Citation>Novi G, Rossi T, Pedemonte E, Saitta L, Rolla C, Roccatagliata L, et al. . Acute Disseminated Encephalomyelitis After SARS-CoV-2 Infection. Neurol Neuroimmunol Neuroinflamm (2020) 7:797. doi:&#xa0;10.1212/NXI.0000000000000797</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000797</ArticleId><ArticleId IdType="pmc">PMC7286650</ArticleId><ArticleId IdType="pubmed">32482781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein O, Elazim AA, Torbey MT. Covid-19 Systemic Infection Exacerbates Pre-Existing Acute Disseminated Encephalomyelitis (ADEM). J Neuroimmunol (2020) 349:577405. doi:&#xa0;10.1016/J.JNEUROIM.2020.577405</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JNEUROIM.2020.577405</ArticleId><ArticleId IdType="pmc">PMC7518115</ArticleId><ArticleId IdType="pubmed">33002725</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavero I, Valentino F, Colombo E, Franciotta D, Ferrandi D, Mussa M, et al. . Acute Myelopathies Associated to SARS-CoV-2 Infection: Viral or Immune-Mediated Damage? Travel Med Infect Dis (2021) 40:102000. doi:&#xa0;10.1016/j.tmaid.2021.102000</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021.102000</ArticleId><ArticleId IdType="pmc">PMC7905382</ArticleId><ArticleId IdType="pubmed">33640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 Ncov-19 Vaccine (Azd1222). Front Immunol (2021) 12:653786. doi:&#xa0;10.3389/fimmu.2021.653786</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.653786</ArticleId><ArticleId IdType="pmc">PMC8107358</ArticleId><ArticleId IdType="pubmed">33981305</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarma D, Bilello LA. A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection Publication Date License A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection. J Clin Pract cases Emergency Med (2020) 4. doi:&#xa0;10.5811/cpcem.2020.5.47937</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/cpcem.2020.5.47937</ArticleId><ArticleId IdType="pmc">PMC7434287</ArticleId><ArticleId IdType="pubmed">32926676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghi A, Ramezani M, Roozbeh M, Darazam IA. Sahraian MA. A Case of Possible Atypical Demyelinating Event of the Central Nervous System Following COVID-19. Mult Scler Relat Disord (2020) 44:102324. doi:&#xa0;10.1016/j.msard.2020.102324</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102324</ArticleId><ArticleId IdType="pmc">PMC7311915</ArticleId><ArticleId IdType="pubmed">32615528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Jones-Lopez EC, Soneji DJ, Azevedo CJ, Patel VR. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis and Myelitis in COVID-19. J Neuro-Ophthalmol (2020) 40:398&#x2013;402. doi:&#xa0;10.1097/WNO.0000000000001049</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNO.0000000000001049</ArticleId><ArticleId IdType="pmc">PMC7382408</ArticleId><ArticleId IdType="pubmed">32604245</ArticleId></ArticleIdList></Reference><Reference><Citation>Corr&#xea;a DG, de Souza Lima FC, da Cruz Bezerra D, Coutinho AC, Hygino da Cruz LC. COVID-19 Associated With Encephalomyeloradiculitis and Positive Anti-Aquaporin-4 Antibodies: Cause or Coincidence? Mult Scler J (2021) 27:973&#x2013;6. doi:&#xa0;10.1177/1352458520949988</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520949988</ArticleId><ArticleId IdType="pubmed">32909895</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw VC, Chander G, Puttanna A. Neuromyelitis Optica Spectrum Disorder Secondary to COVID-19. Br J Hosp Med (2020) 81:1&#x2013;3. doi:&#xa0;10.12968/hmed.2020.0401</Citation><ArticleIdList><ArticleId IdType="doi">10.12968/hmed.2020.0401</ArticleId><ArticleId IdType="pubmed">32990089</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez de Antonio LA, Gonz&#xe1;lez-Su&#xe1;rez I, Fern&#xe1;ndez-Barriuso I, Rabasa P&#xe9;rez M. Para-Infectious Anti-GD2/GD3 IgM Myelitis During the Covid-19 Pandemic: Case Report and Literature Review. Mult Scler Relat Disord (2021) 49:102783. doi:&#xa0;10.1016/j.msard.2021.102783</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.102783</ArticleId><ArticleId IdType="pmc">PMC7826058</ArticleId><ArticleId IdType="pubmed">33513521</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuccio FG, Barra M, Claudio G, Claudio S. A Rare Case of Acute Motor Axonal Neuropathy and Myelitis Related to SARS-CoV-2 Infection. J Neurol (2020) 268:2327&#x2013;30. doi:&#xa0;10.1007/S00415-020-10219-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-020-10219-5</ArticleId><ArticleId IdType="pmc">PMC7497229</ArticleId><ArticleId IdType="pubmed">32940797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci G, Ballerini C, Mechelli R, Bigi R, Rinaldi V, Reni&#xe8; R, et al. . SARS-CoV-2 Meta-Interactome Suggests Disease-Specific, Autoimmune Pathophysiologies and Therapeutic Targets. F1000Research (2020) 9:992. doi:&#xa0;10.12688/f1000research.25593.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.25593.1</ArticleId><ArticleId IdType="pmc">PMC7791351</ArticleId><ArticleId IdType="pubmed">33456761</ArticleId></ArticleIdList></Reference><Reference><Citation>Annibali V, Mechelli R, Romano S, Buscarinu MC, Fornasiero A, Umeton R, et al. . IFN-&#x3b2; and Multiple Sclerosis: From Etiology to Therapy and Back. Cytokine Growth Factor Rev (2015) 26(2):221&#x2013;8. doi:&#xa0;10.1016/j.cytogfr.2014.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.10.010</ArticleId><ArticleId IdType="pubmed">25466632</ArticleId></ArticleIdList></Reference><Reference><Citation>Severa M, Farina C, Salvetti M, Coccia EM. Three Decades of Interferon- &#x3b2; in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection? Front Immunol (2020) 11:1&#x2013;4. doi:&#xa0;10.3389/fimmu.2020.01459</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01459</ArticleId><ArticleId IdType="pmc">PMC7326001</ArticleId><ArticleId IdType="pubmed">32655578</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, M&#xf8;ller R, et al. . Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell (2020) 181:1036&#x2013;1045.e9. doi:&#xa0;10.1016/j.cell.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya D, Liu G, Gack MU. Dysregulation of Type I Interferon Responses in COVID-19. Nat Rev Immunol (2020) 20:397&#x2013;8. doi:&#xa0;10.1038/s41577-020-0346-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0346-x</ArticleId><ArticleId IdType="pmc">PMC7249038</ArticleId><ArticleId IdType="pubmed">32457522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, et al. . DMTs and Covid-19 Severity in MS: A Pooled Analysis From Italy and France. 1Ann Clin Trans Neurol (2021) 8(8):1738&#x2013;44. doi:&#xa0;10.1002/ACN3.51408</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ACN3.51408</ArticleId><ArticleId IdType="pmc">PMC8351392</ArticleId><ArticleId IdType="pubmed">34240579</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, Cao Z, Xie X, Zhang X, Chen JYC, Wang H, et al. . Evasion of Type I Interferon by SARS-CoV-2. Cell Rep (2020) 33:108234. doi:&#xa0;10.1016/j.celrep.2020.108234</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108234</ArticleId><ArticleId IdType="pmc">PMC7501843</ArticleId><ArticleId IdType="pubmed">32979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. . Inborn Errors of Type I IFN Immunity in Patients With Life-Threatening COVID-19. Science (2020) 370(6515). doi:&#xa0;10.1126/science.abd4570</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Zhang Y, Dorgham K, B&#xe9;ziat V, et al. . IgG Autoantibodies Against Type I IFNs in Patients With Severe COVID-19. Science (2020) 370(6515):eabd4585. doi: 10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD. SARS-CoV-2 Is Sensitive to Type I Interferon Pretreatment. J Virol (2020) 94:e01410&#x2013;20. doi: 10.1128/JVI.01410-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01410-20</ArticleId><ArticleId IdType="pmc">PMC7654262</ArticleId><ArticleId IdType="pubmed">32938761</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, et al. . Marked T Cell Activation, Senescence, Exhaustion and Skewing Towards TH17 in Patients With COVID-19 Pneumonia. Nat Commun (2020) 11:3434. doi:&#xa0;10.1038/s41467-020-17292-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17292-4</ArticleId><ArticleId IdType="pmc">PMC7338513</ArticleId><ArticleId IdType="pubmed">32632085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X. COVID-19: Immunopathology and its Implications for Therapy. Nat Rev Immunol (2020) 20:269&#x2013;70. doi:&#xa0;10.1038/s41577-020-0308-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId><ArticleId IdType="pmc">PMC7143200</ArticleId><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacha O, Sallman MA, Evans SE. COVID-19: A Case for Inhibiting IL-17? Nat Rev Immunol (2020) 20:345&#x2013;6. doi:&#xa0;10.1038/s41577-020-0328-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0328-z</ArticleId><ArticleId IdType="pmc">PMC7194244</ArticleId><ArticleId IdType="pubmed">32358580</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S. Comparative Host-Coronavirus Protein Interaction Networks Reveal Pan-Viral Disease Mechanisms. Science (2020) 9403:1&#x2013;38. doi: 10.1126/science.abe9403</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe9403</ArticleId><ArticleId IdType="pmc">PMC7808408</ArticleId><ArticleId IdType="pubmed">33060197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM, Beumer J, Van Der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. . SARS-CoV-2 Productively Infects Human Gut Enterocytes. Science (2020) 369(6499):50&#x2013;4. doi:&#xa0;10.1126/science.abc1669</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1669</ArticleId><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. . Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology (2020) 159(3):944&#x2013;55.E8. doi:&#xa0;10.1053/j.gastro.2020.05.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaldaferri F, Ianiro G, Privitera G, Lopetuso LR, Vetrone LM, Petito V, et al. . The Thrilling Journey of SARS-CoV-2 Into the Intestine: From Pathogenesis to Future Clinical Implications. Inflammatory Bowel Dis (2020) 26(9):1306&#x2013;14. doi:&#xa0;10.1093/ibd/izaa181</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izaa181</ArticleId><ArticleId IdType="pmc">PMC7454647</ArticleId><ArticleId IdType="pubmed">32720978</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra S, Costa C, Eixarch H, Keller CW, Amman L, Mart&#xed;nez-Banaclocha H, et al. . NLRP3 Inflammasome as Prognostic Factor and Therapeutic Target in Primary Progressive Multiple Sclerosis Patients. Brain (2020) 143(5):1414&#x2013;30. doi:&#xa0;10.1093/brain/awaa084</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa084</ArticleId><ArticleId IdType="pubmed">32282893</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, F&#xf6;rster I, et al. . Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation. Immunity (2011) 34(2):213&#x2013;23. doi:&#xa0;10.1016/j.immuni.2011.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.02.006</ArticleId><ArticleId IdType="pubmed">21349431</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares JL, Oliveira EM, Pontillo A. Variants in NLRP3 and NLRC4 Inflammasome Associate With Susceptibility and Severity of Multiple Sclerosis. Mult Scler Relat Disord (2019) 29:26&#x2013;34. doi:&#xa0;10.1016/j.msard.2019.01.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2019.01.023</ArticleId><ArticleId IdType="pubmed">30658261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, Haja Mohideen SM, et al. . A Dynamic Immune Response Shapes COVID-19 Progression. Cell Host Microbe (2020) 27(6):879&#x2013;82. doi:&#xa0;10.1016/j.chom.2020.03.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.03.021</ArticleId><ArticleId IdType="pmc">PMC7192089</ArticleId><ArticleId IdType="pubmed">32359396</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. Front Immunol (2020) 11:1518. doi:&#xa0;10.3389/fimmu.2020.01518</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01518</ArticleId><ArticleId IdType="pmc">PMC7324760</ArticleId><ArticleId IdType="pubmed">32655582</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg DF, te Velde AA. Severe COVID-19: NLRP3 Inflammasome Dysregulated. Front Immunol (2020). doi:&#xa0;10.3389/fimmu.2020.01580</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01580</ArticleId><ArticleId IdType="pmc">PMC7332883</ArticleId><ArticleId IdType="pubmed">32670297</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, Romani L, Bernitsas E. Could Sars-Cov2 Affect MS Progression? Mult Scler Relat Disord (2020) 46:102540. doi:&#xa0;10.1016/j.msard.2020.102540</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102540</ArticleId><ArticleId IdType="pmc">PMC7524432</ArticleId><ArticleId IdType="pubmed">33032060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VAG, et al. . A &#x201c;Candidate-Interactome&#x201d; Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis. PloS One (2013) 8:e63300. doi:&#xa0;10.1371/journal.pone.0063300</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0063300</ArticleId><ArticleId IdType="pmc">PMC3655974</ArticleId><ArticleId IdType="pubmed">23696811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, et al. . Epstein&#x2013;Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends Mol Med (2019) 26(3):1&#x2013;15. doi:&#xa0;10.1016/j.molmed.2019.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2019.11.003</ArticleId><ArticleId IdType="pmc">PMC7106557</ArticleId><ArticleId IdType="pubmed">31862243</ArticleId></ArticleIdList></Reference><Reference><Citation>Belbasis L, Bellou V, Evangelou E, Ioannidis JPA, Tzoulaki I. Environmental Risk Factors and Multiple Sclerosis: An Umbrella Review of Systematic Reviews and Meta-Analyses. Lancet Neurol (2015) 14(3):263&#x2013;73. doi:&#xa0;10.1016/S1474-4422(14)70267-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70267-4</ArticleId><ArticleId IdType="pubmed">25662901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A, Munger KL. Epstein-Barr Virus Infection and Multiple Sclerosis: A Review. J Neuroimmune Pharmacol (2010) 5:271&#x2013;7. doi:&#xa0;10.1007/s11481-010-9201-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-010-9201-3</ArticleId><ArticleId IdType="pubmed">20369303</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, et al. . Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis. PloS Pathog (2013) 9:e1003220. doi:&#xa0;10.1371/JOURNAL.PPAT.1003220</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PPAT.1003220</ArticleId><ArticleId IdType="pmc">PMC3623710</ArticleId><ArticleId IdType="pubmed">23592979</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of Ectopic B-Cell Follicles With Germinal Centers in the Meninges of Patients With Secondary Progressive Multiple Sclerosis. Brain Pathol (2004) 14:164&#x2013;74. doi:&#xa0;10.1111/j.1750-3639.2004.tb00049.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2004.tb00049.x</ArticleId><ArticleId IdType="pmc">PMC8095922</ArticleId><ArticleId IdType="pubmed">15193029</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafini B, Rosicarelli B, Veroni C, Mazzola GA, Aloisi F. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Multiple Sclerosis Brain and Interact Locally With Virus Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism. J Virol (2019) 93:e00980&#x2013;19. doi:&#xa0;10.1128/jvi.00980-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00980-19</ArticleId><ArticleId IdType="pmc">PMC6880158</ArticleId><ArticleId IdType="pubmed">31578295</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. . Meningeal B-Cell Follicles in Secondary Progressive Multiple Sclerosis Associate With Early Onset of Disease and Severe Cortical Pathology. Brain (2007) 130(4):1089&#x2013;104. doi:&#xa0;10.1093/brain/awm038</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm038</ArticleId><ArticleId IdType="pubmed">17438020</ArticleId></ArticleIdList></Reference><Reference><Citation>Pender MP, Csurhes PA, Burrows JM, Burrows SR. Defective T-Cell Control of Epstein&#x2013;Barr Virus Infection in Multiple Sclerosis. Clin Trans Immunol (2017) 6:e126. doi:&#xa0;10.1038/CTI.2016.87</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/CTI.2016.87</ArticleId><ArticleId IdType="pmc">PMC5292561</ArticleId><ArticleId IdType="pubmed">28197337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivadinov R, Cerza N, Hagemeier J, Carl E, Badgett D, Ramasamy DP, et al. . Humoral Response to EBV is Associated With Cortical Atrophy and Lesion Burden in Patients With MS. Neurol - Neuroimmunol Neuroinflamm (2016) 3(1):e190. doi:&#xa0;10.1212/nxi.0000000000000190</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/nxi.0000000000000190</ArticleId><ArticleId IdType="pmc">PMC4708926</ArticleId><ArticleId IdType="pubmed">26770996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner GF, Klein SJ, Zoller H, Peer A, Bellmann R, Joannidis M. Correlation of Interleukin-6 With Epstein&#x2013;Barr Virus Levels in COVID-19. Crit Care (2020) 24:1&#x2013;3. doi:&#xa0;10.1186/S13054-020-03384-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13054-020-03384-6</ArticleId><ArticleId IdType="pmc">PMC7682685</ArticleId><ArticleId IdType="pubmed">33228750</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A, Engelmann I, Moreau AS, Garcia B, Six S, el Kalioubie A, et al. . High Incidence of Epstein&#x2013;Barr Virus, Cytomegalovirus, and Human-Herpes Virus-6 Reactivations in Critically Ill Patients With COVID-19. Infect Dis Now (2021) 51:296&#x2013;9. doi:&#xa0;10.1016/J.IDNOW.2021.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IDNOW.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein&#x2013;Barr Virus Detection in Coronavirus Disease 2019 (COVID-19) Patients. Sci Rep (2021) 11:1&#x2013;7. doi:&#xa0;10.1038/s41598-021-90351-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90351-y</ArticleId><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. . 6-Month Consequences of COVID-19 in Patients Discharged From Hospital: A Cohort Study. Lancet (2021) 397:220&#x2013;32. doi:&#xa0;10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-Acute COVID-19 Syndrome. Nat Med (2021) 27:601&#x2013;6. doi:&#xa0;10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-Month Neurological and Psychiatric Outcomes in 236&#x2009;379 Survivors of COVID-19: A Retrospective Cohort Study Using Electronic Health Records. Lancet Psychiatry (2021) 8:416&#x2013;27. doi:&#xa0;10.1016/S2215-0366(21)00084-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeratne T, Crewther S. Post-COVID 19 Neurological Syndrome (PCNS); a Novel Syndrome With Challenges for the Global Neurology Community. J Neurol Sci (2020) 419:'117179. doi:&#xa0;10.1016/J.JNS.2020.117179</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JNS.2020.117179</ArticleId><ArticleId IdType="pmc">PMC7550857</ArticleId><ArticleId IdType="pubmed">33070003</ArticleId></ArticleIdList></Reference><Reference><Citation>White P. Long COVID: Don&#x2019;t Consign ME/CFS to History. Nature (2020) 587:197. doi:&#xa0;10.1038/D41586-020-03136-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/D41586-020-03136-0</ArticleId><ArticleId IdType="pubmed">33173222</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for Active Epstein-Barr Virus Infection in Patients With Persistent, Unexplained Illnesses: Elevated Anti-Early Antigen Antibodies. Ann Internal Med (1985) 102:1&#x2013;7. doi:&#xa0;10.7326/0003-4819-102-1-</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-102-1-</ArticleId><ArticleId IdType="pubmed">2578266</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus SE, Tosato G, Armstrong G, Lawley T, Preble OT, Henle W, et al. . Persisting Illness and Fatigue in Adults With Evidence of Epstein-Barr Virus Infection. Ann Internal Med (1985) 102:7&#x2013;16. doi:&#xa0;10.7326/0003-4819-102-1-7</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-102-1-7</ArticleId><ArticleId IdType="pubmed">2578268</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs SF, Henry B, Balachandran N, Strayer D, Peterson D, Komaroff AL. Ablashi D V. HHV-6 Reactivation in Chronic Fatigue Syndrome. Lancet (1991) 337:1346&#x2013;7. doi:&#xa0;10.1016/0140-6736(91)93018-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(91)93018-5</ArticleId><ArticleId IdType="pubmed">1674318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablashi DV, Eastman HB, Owen CB, Roman MM, Friedman J, Zabriskie JB, et al. . Frequent HHV-6 Reactivation in Multiple Sclerosis (MS) and Chronic Fatigue Syndrome (CFS) Patients. J Clin Virol (2000) 16:179&#x2013;91. doi:&#xa0;10.1016/S1386-6532(99)00079-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(99)00079-7</ArticleId><ArticleId IdType="pubmed">10738137</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Lipkin WI. Insights From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome May Help Unravel the Pathogenesis of Post-Acute COVID-19 Syndrome. Trends Mol Med (2021) 27(9):895&#x2013;906. doi:&#xa0;10.1016/j.molmed.2021.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K. SSIHMSJDAK. The Chronic Fatigue Syndrome: A Comprehensive Approach to its Definition and Study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med (1994) 121:953&#x2013;9. doi: 10.7326/0003-4819-121-12-199412150-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomas C, Lodge TA, Potter M, Elson JL, Newton JL, Morten KJ. Assessing Cellular Energy Dysfunction in CFS/ME Using a Commercially Available Laboratory Test. Sci Rep (2019) 9:1&#x2013;9. doi:&#xa0;10.1038/s41598-019-47966-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47966-z</ArticleId><ArticleId IdType="pmc">PMC6686017</ArticleId><ArticleId IdType="pubmed">31391529</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Ishii A, Watanabe Y. Neural Dysfunction in Chronic Fatigue Syndrome. Adv Neuroimmune Biol (2013) 4(4):291&#x2013;300. doi:&#xa0;10.3233/NIB-130065</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NIB-130065</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger JR, Pocoski J, Preblick R, Boklage S. Fatigue Heralding Multiple Sclerosis. Mult Scler (2013) 19:1526&#x2013;32. doi:&#xa0;10.1177/1352458513477924</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458513477924</ArticleId><ArticleId IdType="pubmed">23439577</ArticleId></ArticleIdList></Reference><Reference><Citation>Boerio JLJHAC. Pathophysiology D. And Treatment of Fatigue in Multiple Sclerosis. Rev Neurol (2006) 162:311&#x2013;20. doi: 10.1016/s0035-3787(06)75017-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0035-3787(06)75017-2</ArticleId><ArticleId IdType="pubmed">16585886</ArticleId></ArticleIdList></Reference><Reference><Citation>Braley TJ, Chervin RD. Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and Treatment. Sleep (2010) 33:1061. doi:&#xa0;10.1093/SLEEP/33.8.1061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/SLEEP/33.8.1061</ArticleId><ArticleId IdType="pmc">PMC2910465</ArticleId><ArticleId IdType="pubmed">20815187</ArticleId></ArticleIdList></Reference><Reference><Citation>Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, et al. . Safety and Efficacy of Amantadine, Modafinil, and Methylphenidate for Fatigue in Multiple Sclerosis: A Randomized, Crossover, Double-Blind Trial. Lancet Neurol (2021) 20:38. doi:&#xa0;10.1016/S1474-4422(20)30354-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30354-9</ArticleId><ArticleId IdType="pmc">PMC7772747</ArticleId><ArticleId IdType="pubmed">33242419</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Berk M, Puri BK. A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): Is There a Common Cause? Mol Neurobiol (2018) 55:3592&#x2013;609. doi:&#xa0;10.1007/s12035-017-0598-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0598-z</ArticleId><ArticleId IdType="pmc">PMC5842501</ArticleId><ArticleId IdType="pubmed">28516431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaber TA-ZK, Oo WW, Ringrose H. Multiple Sclerosis/Chronic Fatigue Syndrome Overlap: When Two Common Disorders Collide. NeuroRehabilitation (2014) 35:529&#x2013;34. doi:&#xa0;10.3233/NRE-141146</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NRE-141146</ArticleId><ArticleId IdType="pubmed">25238862</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Maes M. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Encephalomyelitis Disseminata/Multiple Sclerosis Show Remarkable Levels of Similarity in Phenomenology and Neuroimmune Characteristics. BMC Med (2013) 11:1&#x2013;23. doi:&#xa0;10.1186/1741-7015-11-205</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-205</ArticleId><ArticleId IdType="pmc">PMC3847236</ArticleId><ArticleId IdType="pubmed">24229326</ArticleId></ArticleIdList></Reference><Reference><Citation>Natelson BH, Johnson SK, DeLuca J, Sisto S, Ellis SP, Hill N, et al. . Reducing Heterogeneity in Chronic Fatigue Syndrome: A Comparison With Depression and Multiple Sclerosis. Clin Infect Dis (1995) 21:1204&#x2013;10. doi:&#xa0;10.1093/CLINIDS/21.5.1204</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CLINIDS/21.5.1204</ArticleId><ArticleId IdType="pubmed">8589144</ArticleId></ArticleIdList></Reference><Reference><Citation>Cliff JM, King EC, Lee J-S, Sep&#xfa;lveda N, Wolf A-S, Kingdon C, et al. . Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Front Immunol (2019) 0:796. doi:&#xa0;10.3389/FIMMU.2019.00796</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2019.00796</ArticleId><ArticleId IdType="pmc">PMC6477089</ArticleId><ArticleId IdType="pubmed">31057538</ArticleId></ArticleIdList></Reference><Reference><Citation>Willing A, Leach OA, Ufer F, Attfield KE, Steinbach K, Kursawe N, et al. . CD8+ MAIT Cells Infiltrate Into the CNS and Alterations in Their Blood Frequencies Correlate With IL-18 Serum Levels in Multiple Sclerosis. Eur J Immunol (2014) 44(10):3119&#x2013;28. doi:&#xa0;10.1002/eji.201344160</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201344160</ArticleId><ArticleId IdType="pubmed">25043505</ArticleId></ArticleIdList></Reference><Reference><Citation>Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, et al. . Cd161highcd8+T Cells Bear Pathogenetic Potential in Multiple Sclerosis. Brain (2011) 134:542&#x2013;54. doi:&#xa0;10.1093/BRAIN/AWQ354</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/BRAIN/AWQ354</ArticleId><ArticleId IdType="pubmed">21216829</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli R, Romano S, Romano C, Morena E, Buscarinu MC, Bigi R, et al. . MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases. Microorganisms (2021) 9:1132. doi:&#xa0;10.3390/MICROORGANISMS9061132</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/MICROORGANISMS9061132</ArticleId><ArticleId IdType="pmc">PMC8225125</ArticleId><ArticleId IdType="pubmed">34074025</ArticleId></ArticleIdList></Reference><Reference><Citation>Vavougios GD. A Data-Driven Hypothesis on the Epigenetic Dysregulation of Host Metabolism by SARS Coronaviral Infection: Potential Implications for the SARS-CoV-2 Modus Operandi. Med Hypotheses (2020) 140:109759. doi:&#xa0;10.1016/j.mehy.2020.109759</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109759</ArticleId><ArticleId IdType="pmc">PMC7177071</ArticleId><ArticleId IdType="pubmed">32344305</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma D, Mel Church T, Swaminathan S. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS CoV-2 Pseudotyped Virus Entry in Epithelial Cells. J Virol (2021) 95(13):e00192&#x2013;21. doi:&#xa0;10.1128/jvi.00192-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00192-21</ArticleId><ArticleId IdType="pmc">PMC8316011</ArticleId><ArticleId IdType="pubmed">33853968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. . Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity. Science (2020) 370(6518):856&#x2013;60. doi:&#xa0;10.1126/science.abd2985</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly JL, Simonetti B, Klein K, Chen K-E, Williamson MK, Ant&#xf3;n-Pl&#xe1;garo C, et al. . Neuropilin-1 is a Host Factor for SARS-CoV-2 Infection. Science (2020) 370(6518):861&#x2013;5. doi:&#xa0;10.1126/science.abd3072</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3072</ArticleId><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HB, Zhang H, Zhang JP, Li Y, Zhao B, Feng GK, et al. . Neuropilin 1 is an Entry Factor That Promotes EBV Infection of Nasopharyngeal Epithelial Cells. Nat Commun (2015) 6:6240. doi:&#xa0;10.1038/ncomms7240</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7240</ArticleId><ArticleId IdType="pmc">PMC4339892</ArticleId><ArticleId IdType="pubmed">25670642</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomona BD, Muellera C, Chaeb WJ, Alabanzaa LM, Bynoea MS. Neuropilin-1 Attenuates Autoreactivity in Experimental Autoimmune Encephalomyelitis. Proc Natl Acad Sci USA (2011) 108(5):2040&#x2013;5. doi:&#xa0;10.1073/pnas.1008721108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008721108</ArticleId><ArticleId IdType="pmc">PMC3033275</ArticleId><ArticleId IdType="pubmed">21245328</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cao Y, Mangalam AK, Guo Y, LaFrance-Corey RG, Gamez JD, et al. . Neuropilin-1 Modulates Interferon-&#x3b3;-Stimulated Signaling in Brain Microvascular Endothelial Cells. J Cell Sci (2016) 129(20):3911&#x2013;21. doi:&#xa0;10.1242/jcs.190702</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.190702</ArticleId><ArticleId IdType="pmc">PMC5087664</ArticleId><ArticleId IdType="pubmed">27591257</ArticleId></ArticleIdList></Reference><Reference><Citation>Illes Z, Gross CC, Geginat J, Bomfim LI, Engdahl E, Gustafsson R, et al. . Increased Serological Response Against Human Herpesvirus 6a Is Associated With Risk for Multiple Sclerosis. Front Immunol (2019) 10:2715. doi:&#xa0;10.3389/fimmu.2019.02715</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02715</ArticleId><ArticleId IdType="pmc">PMC6988796</ArticleId><ArticleId IdType="pubmed">32038605</ArticleId></ArticleIdList></Reference><Reference><Citation>Abad&#xed;as-Granado I, Navarro-Bielsa A, Morales-Callaghan AM, Roc L, Suso-Est&#xed;valez CC, Povar-Echeverr&#xed;a M, et al. . COVID-19-Associated Cutaneous Manifestations: Does Human Herpesvirus 6 Play an Aetiological Role? Br J Dermatol (2021) 184:1187&#x2013;90. doi:&#xa0;10.1111/BJD.19806</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/BJD.19806</ArticleId><ArticleId IdType="pmc">PMC8014469</ArticleId><ArticleId IdType="pubmed">33420720</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumah M, Rahman F, Figgie M, Prasad A, Zampino A, Fadhil A, et al. . COVID-19, HHV6 and MOG Antibody: A Perfect Storm. J Neuroimmunol (2021) 353:577521. doi:&#xa0;10.1016/j.jneuroim.2021.577521</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577521</ArticleId><ArticleId IdType="pmc">PMC7879032</ArticleId><ArticleId IdType="pubmed">33607505</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira JP, Sequeira J, Brito MJ. Postinfectious Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and Myelitis. J Child Neurol (2017) 996&#x2013;9. doi:&#xa0;10.1177/0883073817724927</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073817724927</ArticleId><ArticleId IdType="pubmed">28820014</ArticleId></ArticleIdList></Reference><Reference><Citation>Fierz W. Multiple Sclerosis: An Example of Pathogenic Viral Interaction? Virol J (2017) 14:42. doi:&#xa0;10.1186/s12985-017-0719-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-017-0719-3</ArticleId><ArticleId IdType="pmc">PMC5330019</ArticleId><ArticleId IdType="pubmed">28241767</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues LS, Nali LH da S, Leal COD, Sabino EC, Lacerda EM, Kingdon CC, et al. . HERV-K and HERV-W Transcriptional Activity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Autoimmun Highlights (2019) 10:1&#x2013;5. doi:&#xa0;10.1186/S13317-019-0122-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13317-019-0122-8</ArticleId><ArticleId IdType="pmc">PMC7065355</ArticleId><ArticleId IdType="pubmed">32257068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung H-P, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, et al. . Efficacy and Safety of Temelimab in Multiple Sclerosis: Results of a Randomized Phase 2b and Extension Study. Mult Scler (2021) 135245852110249. doi:&#xa0;10.1177/13524585211024997</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585211024997</ArticleId><ArticleId IdType="pubmed">34240656</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolei A, Ibba G, Piu C, Serra C. Expression of HERV Genes as Possible Biomarker and Target in Neurodegenerative Diseases. Int J Mol Sci (2019) 20:3706. doi:&#xa0;10.3390/IJMS20153706</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IJMS20153706</ArticleId><ArticleId IdType="pmc">PMC6696274</ArticleId><ArticleId IdType="pubmed">31362360</ArticleId></ArticleIdList></Reference><Reference><Citation>Charvet B, Brunel J, Pierquin J, Mathieu C, Perron H. SARS-CoV-2 Induces Transcription of Human Endogenous Retrovirus RNA Followed by Type W Envelope Protein Expression in Human Lymphoid Cells. Res Square (2021). doi:&#xa0;10.21203/RS.3.RS-301236/V1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/RS.3.RS-301236/V1</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestrieri E, Minutolo A, Petrone V, Fanelli M, Iannetta M, Malagnino V, et al. . Evidence of the Pathogenic HERV-W Envelope Expression in T Lymphocytes in Association With the Respiratory Outcome of COVID-19 Patients. EBioMedicine (2021) 66:103341. doi:&#xa0;10.1016/J.EBIOM.2021.103341</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EBIOM.2021.103341</ArticleId><ArticleId IdType="pmc">PMC8082064</ArticleId><ArticleId IdType="pubmed">33867312</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shehawi AM, Alotaibi SS, Elseehy MM. Genomic Study of COVID-19 Corona Virus Excludes Its Origin From Recombination or Characterized Biological Sources and Suggests a Role for HERVS in Its Wide Range Symptoms. Cytol Genet (2020) 54:588. doi:&#xa0;10.3103/S0095452720060031</Citation><ArticleIdList><ArticleId IdType="doi">10.3103/S0095452720060031</ArticleId><ArticleId IdType="pmc">PMC7810191</ArticleId><ArticleId IdType="pubmed">33487779</ArticleId></ArticleIdList></Reference><Reference><Citation>Palao M, Fern&#xe1;ndez-D&#xed;az E, Gracia-Gil J, Romero-S&#xe1;nchez C, D&#xed;az-Maroto I, Segura T. Multiple Sclerosis Following SARS-CoV-2 Infection. Mult Scler Relat Disord (2020) 45:102377. doi: 10.1016/j.msard.2020.102377</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102377</ArticleId><ArticleId IdType="pmc">PMC7340057</ArticleId><ArticleId IdType="pubmed">32698095</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoso YD, Pacheco FAS, Silveira GL, Oliveira RA, Carvalho VM, Martimbianco ALC. COVID-19 in a Temporal Relation to the Onset of Multiple Sclerosis. Mult Scler Relat Disord (2021) 50:102863. doi:&#xa0;10.1016/j.msard.2021.102863</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.102863</ArticleId><ArticleId IdType="pmc">PMC7902206</ArticleId><ArticleId IdType="pubmed">33662859</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore L, Ghannam M, Manousakis G. A First Presentation of Multiple Sclerosis With Concurrent COVID-19 Infection. eNeurologicalSci (2021) 22:100299. doi:&#xa0;10.1016/j.ensci.2020.100299</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2020.100299</ArticleId><ArticleId IdType="pmc">PMC7717878</ArticleId><ArticleId IdType="pubmed">33313429</ArticleId></ArticleIdList></Reference><Reference><Citation>Naser Moghadasi A. A 31-Year-Old Female Patient With Concurrent Clinical Onset of Multiple Sclerosis and COVID-19: Possible Role of SARS-CoV-2 in the Pathogenesis of Multiple Sclerosis. Autoimmun Rev (2021) 20:102803. doi:&#xa0;10.1016/j.autrev.2021.102803</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102803</ArticleId><ArticleId IdType="pmc">PMC7960029</ArticleId><ArticleId IdType="pubmed">33737090</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhani N, Tremlett H. The Multiple Sclerosis Prodrome. Nat Rev Neurol (2021) 17:1&#x2013;7. doi:&#xa0;10.1038/s41582-021-00519-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-021-00519-3</ArticleId><ArticleId IdType="pmc">PMC8324569</ArticleId><ArticleId IdType="pubmed">34155379</ArticleId></ArticleIdList></Reference><Reference><Citation>Steelman AJ. Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation. Front Immunol (2015) 6:520. doi:&#xa0;10.3389/fimmu.2015.00520</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00520</ArticleId><ArticleId IdType="pmc">PMC4609887</ArticleId><ArticleId IdType="pubmed">26539193</ArticleId></ArticleIdList></Reference><Reference><Citation>Buljevac D, Flach HZ, Hop WCJ, Hijdra D, Laman JD, Savelkoul HFJ, et al. . Prospective Study on the Relationship Between Infections and Multiple Sclerosis Exacerbations. Brain (2002) 125(5):952&#x2013;60. doi:&#xa0;10.1093/brain/awf098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf098</ArticleId><ArticleId IdType="pubmed">11960885</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrodan M, Alessandro L, Farez MF, Correale J. The Role of Infections in Multiple Sclerosis. Mult Scler J (2019) 25(7):891&#x2013;901. doi:&#xa0;10.1177/1352458518823940</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458518823940</ArticleId><ArticleId IdType="pubmed">30638421</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards S, Zvartau M, Clarke H, Irving W, Blumhardt LD. Clinical Relapses and Disease Activity on Magnetic Resonance Imaging Associated With Viral Upper Respiratory Tract Infections in Multiple Sclerosis. J Neurol Neurosurg Psychiatry (1998) 64:736&#x2013;41. doi:&#xa0;10.1136/jnnp.64.6.736</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.64.6.736</ArticleId><ArticleId IdType="pmc">PMC2170117</ArticleId><ArticleId IdType="pubmed">9647301</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale J, Fiol M, Gilmore W. The Risk of Relapses in Multiple Sclerosis During Systemic Infections. Neurology (2006) 67(4):652&#x2013;9. doi:&#xa0;10.1212/01.wnl.0000233834.09743.3b</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000233834.09743.3b</ArticleId><ArticleId IdType="pubmed">16870812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneider M, Lisovskaja V, Lycke J, Malmestr&#xf6;m C, Jakobsen JK, Nerman O, et al. . Upper Respiratory Infections and MRI Activity in Relapsing-Remitting MS. Mult Scler (2015) 45(2):83&#x2013;9. doi: 10.1159/000437371</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000437371</ArticleId><ArticleId IdType="pubmed">26316226</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G, et al. . Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. Lancet Neurol (2018) 17:162&#x2013;73. doi: 10.1016/S1474-4422(17)30470-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30470-2</ArticleId><ArticleId IdType="pubmed">29275977</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrower BW. Relapse Management in Multiple Sclerosis. Neurologist (2009) 15:1&#x2013;5. doi:&#xa0;10.1097/NRL.0B013E31817ACF1A</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NRL.0B013E31817ACF1A</ArticleId><ArticleId IdType="pubmed">19131851</ArticleId></ArticleIdList></Reference><Reference><Citation>Garjani A, Middleton RM, Hunter R, Tuite- KA, Coles A, Dobson R, et al. . COVID-19 Is Associated With New Symptoms of Multiple Sclerosis that Are Prevented by Disease Modifying Therapies. Mult Scler Relat Disord (2021) 52:102939. doi: 10.1016/j.msard.2021.102939</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.102939</ArticleId><ArticleId IdType="pmc">PMC9585399</ArticleId><ArticleId IdType="pubmed">34010764</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. . COVID-19 Outcomes in MS: Observational Study of Early Experience From NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm (2020) 7(5). doi:&#xa0;10.1212/NXI.0000000000000835</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000835</ArticleId><ArticleId IdType="pmc">PMC7357412</ArticleId><ArticleId IdType="pubmed">32646885</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva A, Barcella V, Benatti SV, Capobianco M, Capra R, Cinque P, et al. . Vaccinations in Patients With Multiple Sclerosis: A Delphi Consensus Statement. Mult Scler J (2021) 27:347&#x2013;59. doi:&#xa0;10.1177/1352458520952310</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520952310</ArticleId><ArticleId IdType="pubmed">32940128</ArticleId></ArticleIdList></Reference><Reference><Citation>Etemadifar M, Sedaghat N, Aghababaee A, Kargaran PK, Maracy MR, Ganjalikhani-Hakemi M, et al. . COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight With No Bystander Effect? Mult Scler Relat Disord (2021) 51:102915. doi:&#xa0;10.1016/j.msard.2021.102915</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.102915</ArticleId><ArticleId IdType="pmc">PMC7980521</ArticleId><ArticleId IdType="pubmed">33799284</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP. An Italian Programme for COVID-19 Infection in Multiple Sclerosis. Lancet Neurol (2020) 19:481&#x2013;2. doi:&#xa0;10.1016/S1474-4422(20)30147-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30147-2</ArticleId><ArticleId IdType="pmc">PMC7191287</ArticleId><ArticleId IdType="pubmed">32359409</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, et al. . COVID-19 Among Patients With Multiple Sclerosis. Neurol - Neuroimmunol Neuroinflamm (2021) 8:e1001. doi:&#xa0;10.1212/nxi.0000000000001001</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/nxi.0000000000001001</ArticleId><ArticleId IdType="pmc">PMC8142838</ArticleId><ArticleId IdType="pubmed">34016734</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim SSA. Oliveira T De. New SARS-CoV-2 Variants &#x2014; Clinical, Public Health, and Vaccine Implications. N Engl J Med (2021) 384:1866&#x2013;8. doi:&#xa0;10.1056/NEJMC2100362</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMC2100362</ArticleId><ArticleId IdType="pmc">PMC8008749</ArticleId><ArticleId IdType="pubmed">33761203</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero-Romero S, Ascherio A, Lebrun-Fr&#xe9;nay C. Vaccinations in Multiple Sclerosis Patients Receiving Disease-Modifying Drugs. Curr Opin Neurol (2021) 34:322&#x2013;8. doi:&#xa0;10.1097/WCO.0000000000000929</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000929</ArticleId><ArticleId IdType="pubmed">33709979</ArticleId></ArticleIdList></Reference><Reference><Citation>Achiron A, Dolev M, Menascu S, Zohar D-N, Dreyer-Alster S, Miron S, et al. . COVID-19 Vaccination in Patients With Multiple Sclerosis: What We Have Learnt by February 2021. Mult Scler (2021) 27:864&#x2013;70. doi:&#xa0;10.1177/13524585211003476</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585211003476</ArticleId><ArticleId IdType="pmc">PMC8114441</ArticleId><ArticleId IdType="pubmed">33856242</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotan I, Wilf-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 Vaccine in Multiple Sclerosis: Early Experience From a Tertiary MS Center in Israel. Eur J Neurol (2021), ene.15028. doi:&#xa0;10.1111/ENE.15028</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ENE.15028</ArticleId><ArticleId IdType="pmc">PMC8444776</ArticleId><ArticleId IdType="pubmed">34288285</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, et al. . Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases. JAMA Neurol (2014) 71:1506&#x2013;13. doi:&#xa0;10.1001/jamaneurol.2014.2633</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2633</ArticleId><ArticleId IdType="pubmed">25329096</ArticleId></ArticleIdList></Reference><Reference><Citation>Confavreux C, Suissa S, Saddler P, Bourd&#xe8;s V, Vukusic S. Vaccines in Multiple Sclerosis Study Group. Vaccinations and Risk of Relapses in Multiple Sclerosis. N Engl J Med (2001) 344:319&#x2013;26. doi: 10.1056/NEJM200102013440501</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200102013440501</ArticleId><ArticleId IdType="pubmed">11172162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristori G, Mechelli R, Salvetti M. Association Between Vaccines and Neuroinflammation: Time, Risks, and Benefits. JAMA Neurol (2015) 72:605&#x2013;5. doi:&#xa0;10.1001/JAMANEUROL.2015.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANEUROL.2015.71</ArticleId><ArticleId IdType="pubmed">25961176</ArticleId></ArticleIdList></Reference><Reference><Citation>Confavreux C, Suissa S, Saddier P, Bourd&#xe8;s V, Vukusic S. Vaccinations and the Risk of Relapse in Multiple Sclerosis. N Engl J Med (2009) 344:319&#x2013;26. doi:&#xa0;10.1056/NEJM200102013440501</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200102013440501</ArticleId><ArticleId IdType="pubmed">11172162</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttinelli C, Salvetti M, Ristori G. Vaccinations and Multiple Sclerosis. N Engl J Med (2001) 344:1795&#x2013;6. doi: 10.1056/NEJM200106073442313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200106073442313</ArticleId><ArticleId IdType="pubmed">11396455</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvetti M, Pisani A, Bastianello S, Millefiorini E, Buttinelli C, Pozzilli C. Clinical and MRI Assessment of Disease Activity in Patients With Multiple Sclerosis After Influenza Vaccination. J Neurol (1995) 242:143&#x2013;6. doi:&#xa0;10.1007/BF00936886</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00936886</ArticleId><ArticleId IdType="pubmed">7751856</ArticleId></ArticleIdList></Reference><Reference><Citation>Havla J, Schultz Y, Zimmermann H, Hohlfeld R, Danek A, K&#xfc;mpfel T. First Manifestation of Multiple Sclerosis After Immunization With the Pfizer-BioNTech COVID-19 Vaccine. J Neurol (2021) 1:1. doi:&#xa0;10.1007/S00415-021-10648-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-021-10648-W</ArticleId><ArticleId IdType="pmc">PMC8193159</ArticleId><ArticleId IdType="pubmed">34115170</ArticleId></ArticleIdList></Reference><Reference><Citation>Woopen C, Schleu&#xdf;ner K, Akg&#xfc;n K, Ziemssen T. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Front Immunol (2021) 0:701752. doi:&#xa0;10.3389/FIMMU.2021.701752</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.701752</ArticleId><ArticleId IdType="pmc">PMC8256163</ArticleId><ArticleId IdType="pubmed">34234787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. . Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study. Neurology (2020) 95:e1999&#x2013;2008. doi:&#xa0;10.1212/WNL.0000000000010380</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010380</ArticleId><ArticleId IdType="pmc">PMC7843152</ArticleId><ArticleId IdType="pubmed">32727835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabalza A, C&#xe1;rdenas-Robledo S, Tagliani P, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, et al. . COVID-19 in Multiple Sclerosis Patients: Susceptibility, Severity Risk Factors and Serological Response. Eur J Neurol (2020) 28(10):3384&#x2013;95. doi:&#xa0;10.1111/ene.14690</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14690</ArticleId><ArticleId IdType="pubmed">33340215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Schiavetti I, Landi D, Carmisciano L, de RN, Cordioli C, et al. . SARS-CoV-2 Serology After COVID-19 in Multiple Sclerosis: An International Cohort Study. Mult Scler (2021) 135245852110353. doi:&#xa0;10.1177/13524585211035318</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585211035318</ArticleId><ArticleId IdType="pubmed">34328824</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte WL. Attenuation of Antibody Response to SARS-CoV-2 Infection in Patients With Multiple Sclerosis on Ocrelizumab: A Case-Control Study. Mult Scler Relat Disord (2021) 52:103014. doi:&#xa0;10.1016/J.MSARD.2021.103014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.103014</ArticleId><ArticleId IdType="pmc">PMC8102087</ArticleId><ArticleId IdType="pubmed">34000684</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigaut K, Kremer L, Fabacher T, Lanotte L, Fleury M-C, Collongues N. Seze J De. Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti&#x2013;SARS-CoV-2 Antibodies. Neurol - Neuroimmunol Neuroinflamm (2021) 8:e1055. doi:&#xa0;10.1212/NXI.0000000000001055</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001055</ArticleId><ArticleId IdType="pmc">PMC8362343</ArticleId><ArticleId IdType="pubmed">34321333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigaut K, Kremer L, Fleury M, Lanotte L, Collongues N, de Seze J. Impact of Disease-Modifying Treatments on Humoral Response After COVID-19 Vaccination: A Mirror of the Response After SARS-CoV-2 Infection. Rev Neurol (2021) S0035-3787(21):00569&#x2013;5. doi:&#xa0;10.1016/j.neurol.2021.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2021.05.001</ArticleId><ArticleId IdType="pmc">PMC8206590</ArticleId><ArticleId IdType="pubmed">34172292</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo A, Capuano R, Donnarumma G, Bisecco A, Grimaldi E, Conte M, et al. . Preliminary Evidence of Blunted Humoral Response to SARS-CoV-2 mRNA Vaccine in Multiple Sclerosis Patients Treated With Ocrelizumab. Neurol Sci (2021) 42:3523&#x2013;6. doi:&#xa0;10.1007/s10072-021-05397-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05397-7</ArticleId><ArticleId IdType="pmc">PMC8203306</ArticleId><ArticleId IdType="pubmed">34128150</ArticleId></ArticleIdList></Reference><Reference><Citation>Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. . Humoral Immune Response to COVID-19 mRNA Vaccine in Patients With Multiple Sclerosis Treated With High-Efficacy Disease-Modifying Therapies. Ther Adv Neurol Disord (2021) 14. doi:&#xa0;10.1177/17562864211012835</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562864211012835</ArticleId><ArticleId IdType="pmc">PMC8072850</ArticleId><ArticleId IdType="pubmed">34035836</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttari F, Bruno A, Dolcetti E, Azzolini F, Bellantonio P, Centonze D, et al. . COVID-19 Vaccines in Multiple Sclerosis Treated With Cladribine or Ocrelizumab. Mult Scler Relat Disord (2021) 52:102983. doi:&#xa0;10.1016/j.msard.2021.102983</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.102983</ArticleId><ArticleId IdType="pmc">PMC8093161</ArticleId><ArticleId IdType="pubmed">33990054</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreri S, Lazzarin S, Zanetta C, Nozzolillo A, Filippi M, Moiola L. Serological Response to SARS-CoV-2 Vaccination in Multiple Sclerosis Patients Treated With Fingolimod or Ocrelizumab: An Initial Real-Life Experience. J Neurol (2021) 1:1&#x2013;5. doi:&#xa0;10.1007/S00415-021-10663-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-021-10663-X</ArticleId><ArticleId IdType="pmc">PMC8241206</ArticleId><ArticleId IdType="pubmed">34189719</ArticleId></ArticleIdList></Reference><Reference><Citation>Drulovic J, Ivanovic J, Martinovic V, Tamas O, Veselinovic N, Cujic D, et al. . Humoral Response to Sars-Cov-2 and Covid-19 Vaccines in Patients With Multiple Sclerosis Treatted With Immune Reconstitution Therapies. Mult Scler Relat Disord (2021) 54:103150. doi:&#xa0;10.1016/J.MSARD.2021.10315</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.10315</ArticleId><ArticleId IdType="pmc">PMC8280377</ArticleId><ArticleId IdType="pubmed">34298478</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, et al. . Effect of SARS-CoV-2 mRNA Vaccination in MS Patients Treated With Disease Modifying Therapies. SSRN Electron J (2021). doi:&#xa0;10.2139/SSRN.3886420</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/SSRN.3886420</ArticleId><ArticleId IdType="pmc">PMC8456129</ArticleId><ArticleId IdType="pubmed">34563483</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. . Impact of SARS-CoV-2 Variants on the Total CD4+ and CD8+ T&#xa0;cell Reactivity in Infected or Vaccinated Individuals. Cell Rep Med (2021) 2:100355. doi:&#xa0;10.1016/J.XCRM.2021.100355</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.XCRM.2021.100355</ArticleId><ArticleId IdType="pmc">PMC8249675</ArticleId><ArticleId IdType="pubmed">34230917</ArticleId></ArticleIdList></Reference><Reference><Citation>Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. . SARS-CoV-2 Variants of Concern Partially Escape Humoral But Not T Cell Responses in COVID-19 Convalescent Donors and Vaccine Recipients. Sci Immunol (2021) 6:1750. doi:&#xa0;10.1126/SCIIMMUNOL.ABJ1750</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIIMMUNOL.ABJ1750</ArticleId><ArticleId IdType="pmc">PMC9268159</ArticleId><ArticleId IdType="pubmed">34035118</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kister I, Krogsgaard M, Mulligan MJ, Patskovsky Y, Voloshyna I, Ferstler N, et al. . Preliminary Results of Ongoing, Prospective Study of Antibody and T-Cell Responses to SARS-CoV-2 in Patients With MS on Ocrelizumab or Other Disease-Modifying Therapies, in: American Academy of Neurology 73rd Annual Meeting (2021). Available at: https://www.aan.com/siteassets/home-page/conferences-and-community/annual-meeting/abstracts-and-awards/abstracts/2021-emerging-science-abstracts.pdf (Accessed August 2, 2021).</Citation></Reference><Reference><Citation>Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. . Altered Cellular and Humoral Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients With Multiple Sclerosis on Anti-CD20 Therapy. doi:&#xa0;10.1101/2021.06.23.21259389</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.23.21259389</ArticleId><ArticleId IdType="pmc">PMC8604727</ArticleId><ArticleId IdType="pubmed">34522051</ArticleId></ArticleIdList></Reference><Reference><Citation>Suwanwongse K, Shabarek N. Benign Course of COVID-19 in a Multiple Sclerosis Patient Treated With Ocrelizumab. Mult Scler Relat Disord (2020) 42:102201. doi: 10.1016/j.msard.2020.102201</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102201</ArticleId><ArticleId IdType="pmc">PMC7227515</ArticleId><ArticleId IdType="pubmed">32480327</ArticleId></ArticleIdList></Reference><Reference><Citation>Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, et al. . COVID-19 in a MS Patient Treated With Ocrelizumab: Does Immunosuppression Have a Protective Role? Mult Scler Relat Disord (2020) 42:9&#x2013;10. doi:&#xa0;10.1016/j.msard.2020.102120</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102120</ArticleId><ArticleId IdType="pmc">PMC7156942</ArticleId><ArticleId IdType="pubmed">32315980</ArticleId></ArticleIdList></Reference><Reference><Citation>Centonze D, Rocca MA, Gasperini C, Kappos L, Hartung H-P, Magyari M, et al. . Disease-Modifying Therapies and SARS-CoV-2 Vaccination in Multiple Sclerosis: An Expert Consensus. J Neurol (2021) 10:1. doi:&#xa0;10.1007/S00415-021-10545-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-021-10545-2</ArticleId><ArticleId IdType="pmc">PMC8038920</ArticleId><ArticleId IdType="pubmed">33844056</ArticleId></ArticleIdList></Reference><Reference><Citation>Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, et al. . A Noninflammatory mRNA Vaccine for Treatment of Experimental Autoimmune Encephalomyelitis. Science (2021) 371:145&#x2013;53. doi:&#xa0;10.1126/SCIENCE.AAY3638</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.AAY3638</ArticleId><ArticleId IdType="pubmed">33414215</ArticleId></ArticleIdList></Reference><Reference><Citation>Drayman N, DeMarco JK, Jones KA, Azizi S-A, Froggatt HM, Tan K, et al. . Masitinib is a Broad Coronavirus 3CL Inhibitor That Blocks Replication of SARS-CoV-2. Science (2021) 373(6557):931&#x2013;6. doi:&#xa0;10.1126/SCIENCE.ABG5827</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ABG5827</ArticleId><ArticleId IdType="pmc">PMC8809056</ArticleId><ArticleId IdType="pubmed">34285133</ArticleId></ArticleIdList></Reference><Reference><Citation>Naser Moghadasi A. COVID-19-Related Autoimmune Disorders of Central Nervous System (CRAD-C): Is it a New Entity? Autoimmun Rev (2021) 20:102888. doi:&#xa0;10.1016/J.AUTREV.2021.102888</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AUTREV.2021.102888</ArticleId><ArticleId IdType="pmc">PMC8253721</ArticleId><ArticleId IdType="pubmed">34229045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavine JS, Bjornstad ON, Antia R. Immunological Characteristics Govern the Transition of COVID-19 to Endemicity. Science (2021) 371:741&#x2013;5. doi:&#xa0;10.1126/SCIENCE.ABE6522</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ABE6522</ArticleId><ArticleId IdType="pmc">PMC7932103</ArticleId><ArticleId IdType="pubmed">33436525</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>